SINGAPORE

新加坡

,

，

June 30, 2026

2026年6月30日

/PRNewswire/ -- ALR Technologies SG Ltd ('ALRT' or the 'Company') (OTC: ALRTF), the diabetes management company, announces it has entered into a Letter of Intent ('LOI') to acquire 100% equity of CGM Medical Technology Singapore Pte. Ltd. ('CGM Medical Singapore') and assets of CGM Medical Technology Shenzhen Ltd ('CGM Medical Shenzhen') for an aggregate purchase price of 200 million ordinary shares and US$45 million, payable upon certain conditions being met (collectively the 'Transactions')..

/美通社/ -- 糖尿病管理公司 ALR Technologies SG Ltd（“ALRT”或“公司”）（OTC: ALRTF）宣布，已签署一份意向书（“LOI”），拟以2亿股普通股及4,500万美元的总收购价，收购 CGM Medical Technology Singapore Pte. Ltd.（“CGM Medical Singapore”）的100%股权以及 CGM Medical Technology Shenzhen Ltd（“CGM Medical Shenzhen”）的资产，该对价将在满足特定条件后支付（统称“交易”）。

'The acquisition of CGM Medical will make ALRT a fully integrated diabetes company from start to finish' commented Sidney Chan, Chairman and CEO of ALRT. 'We will own the intellectual property and technology to produce the continuous glucose monitors ('CGM') used in the GluCurve Pet CGM and the future human health CGM we will be launching.

“收购CGM Medical将使ALRT成为一家从头到尾完全整合的糖尿病公司。”ALRT董事长兼首席执行官Sidney Chan评论道。“我们将拥有用于GluCurve宠物连续血糖监测仪（CGM）以及我们即将推出的人用健康连续血糖监测仪（CGM）的知识产权和技术。”

The acquisition will enable us to increase margins and have full control of our products and services. The expertise of CGM Medical will also contribute to the design, development, and commercialization of other medical devices for diabetes management and additional chronic diseases.'.

此次收购将使我们能够提高利润率，并对我们的产品和服务拥有完全的控制权。CGM Medical 的专业知识也将有助于糖尿病管理及其他慢性疾病相关其他医疗器械的设计、开发和商业化。

Under the terms of the LOI, ALRT has agreed to purchase CGM Medical Singapore for 200 million ordinary shares of ALRT to be issued upon completion of a definitive agreement, and an aggregate of US$40,000,000 in the form of an unsecured, non-interest-bearing promissory note payable as an earn out as described below..

根据意向书条款，ALRT 同意通过发行 2 亿股 ALRT 普通股（在签署最终协议后发行）以及一张总额为 4,000 万美元的无担保、不计息本票（作为下文所述的盈利支付对价）的方式，收购 CGM Medical Singapore。

Utilizing the licenses, intellectual property, personnel, and expertise of CGM Medical Singapore, ALRT will seek to build a world class manufacturing facility in the Johor-Singapore Special Economic Zone (JS-SEZ) at the close of the transaction. When the automated facility reaches rated production of five hundred thousand (500,000) CGMs per month, ALRT will begin making monthly payments consisting of 25% of the free cash flow generated by ALRT until the US$40,000,000 has been paid in full.

ALRT将利用CGM Medical Singapore的许可、知识产权、人员及专业知识，在交易完成时于新山—新加坡经济特区（JS-SEZ）建设世界一流的制造设施。当该自动化设施达到每月五十万（500,000）个连续血糖监测仪（CGM）的额定产能时，ALRT将开始按月支付款项，金额为ALRT所产生的自由现金流的25%，直至4000万美元全额付清为止。

These payments will be deferred until the payments for CGM Medical Shenzhen are completed..

这些款项将延期支付，直至完成对CGM Medical Shenzhen的付款。

Furthermore, ALRT will acquire assets of CGM Medical Shenzhen for a cash payment of up to US$5,000,000. At closing ALRT will pay CGM Medical Shenzhen US$1,000,000 and the balance will be paid out as 25% of the free cash flow of ALR Technologies SG Ltd. until the remaining amount (up to US$4,000,000) is fully paid subject to the conditions described below..

此外，ALRT将以最高500万美元的现金对价收购CGM Medical Shenzhen的资产。在交割时，ALRT将向CGM Medical Shenzhen支付100万美元，剩余款项（最高400万美元）将以ALR Technologies SG Ltd.自由现金流的25%进行支付，直至全部付清，但须满足下述条件。

ALRT has initiated the purchase of additional automation equipment for US$1.65M to be utilized in the CGM Medical Shenzhen operation located at the InnoMax (a medical device manufacturing subsidiary of Foxconn) facility in Shenzhen that produces the CGMs used in the GluCurve Pet CGM. This equipment is expected to increase the rated production capacity to 300,000 units per month, at which time the acquisition of CGM Medical Shenzhen will close and ALRT will initiate the monthly payments consisting of 25% of the free cash flow generated by ALRT for the remaining amount (up to US$4,000,000).

ALRT已启动采购额外自动化设备的计划，金额为165万美元，用于位于深圳InnoMax（富士康旗下医疗设备制造子公司）工厂的CGM Medical深圳运营部门，该工厂生产用于GluCurve Pet CGM的连续血糖监测仪。预计该设备将使额定月产能提升至30万台。届时，对CGM Medical深圳的收购将完成交割，ALRT将开始按月支付剩余款项（最高不超过400万美元），每月支付金额为ALRT产生的自由现金流的25%。

The production will be used exclusively to supply units for the ALRT GluCurve Pet CGM and future human CGM, supporting the Company's commercialization and growth..

该生产线将专门用于为ALRT GluCurve宠物连续血糖监测系统（CGM）及未来的人用连续血糖监测系统提供设备，以支持公司的商业化进程和业务增长。

Closing of the acquisition of CGM Medical Singapore will be subject to several conditions, including but not limited to, negotiation and execution of a definitive agreement, completion of satisfactory due diligence by ALRT, the receipt of all required regulatory and third-party approvals, and certain other conditions.

收购CGM Medical Singapore的完成将取决于多项条件，包括但不限于：谈判并签署最终协议、ALRT完成令人满意的尽职调查、获得所有必需的监管机构和第三方批准，以及其他某些条件。

ALRT anticipates entering into a definitive agreement to acquire CGM Medical Singapore by July 31, 2026, and a completion date of August 31, 2026..

ALRT预计将于2026年7月31日前就收购CGM Medical Singapore签署最终协议，并于2026年8月31日完成交易。

Closing of the acquisition of CGM Medical Shenzhen will be subject to several conditions, including but not limited to CGM Medical Shenzhen reaching a rated production capacity of 300,000 CGMs per month, finalization of structure of the acquisition, negotiation and execution of a definitive agreement, completion of satisfactory due diligence by ALRT, approval by the boards of directors of both companies, and the receipt of all required regulatory and third-party approvals.

收购CGM Medical Shenzhen的完成将取决于多项条件，包括但不限于：CGM Medical Shenzhen实现每月30万台连续血糖监测仪（CGM）的额定产能；确定收购结构；谈判并签署最终协议；ALRT完成令人满意的尽职调查；双方董事会批准；以及获得所有必要的监管机构和第三方批准。

ALRT anticipates entering into a definitive agreement to acquire CGM Medical Shenzhen by August 31, 2026, and a completion date of January 31, 2027..

ALRT预计将于2026年8月31日前就收购深圳CGM医疗签署最终协议，并于2027年1月31日完成交易。

About CGM Medical Technology Shenzhen Ltd

关于CGM医疗科技深圳有限公司

CGM Medical Technology Shenzhen is a medical device company specializing in the production of continuous glucose monitoring devices for diabetes management, as well as other wearable medical devices. Its key focus is developing an accurate and affordable continuous glucose monitoring (CGM) device for diabetes management..

深圳CGM医疗科技有限公司是一家医疗器械公司，专注于生产用于糖尿病管理的连续血糖监测设备以及其他可穿戴医疗设备。其核心重点是开发一种准确且经济实惠的连续血糖监测（CGM）设备，用于糖尿病管理。

About CGM Medical Technology Singapore Pte. Ltd

关于CGM医疗科技新加坡私人有限公司

Staffed with managers and experts with a wealth of experience in biomedical engineering and info technology, CGM Medical Technology Singapore is an innovative medical device technology company that provides medical device development services, technology transfer, software development, industrial applications of artificial intelligence, and upscaling of manufacturing operations.

CGM Medical Technology Singapore 是一家创新的医疗器械技术公司，拥有在生物医学工程和信息技术领域经验丰富的管理者和专家，提供医疗器械开发服务、技术转让、软件开发、人工智能的工业应用以及制造业务的规模化扩展。

.

。

In 2025, CGM Medical assisted ALR Technologies SG Ltd in developing GluCurve Pet CGM, the first and only diabetic monitoring system built specifically for veterinary use on cats and dogs. The partnership culminated in the successful commercial launch of GluCurve Pet CGM in May 2026.

2025年，CGM Medical协助ALR Technologies SG Ltd开发了GluCurve Pet CGM，这是首款且唯一专为猫狗兽医用途设计的糖尿病监测系统。双方合作于2026年5月成功实现了GluCurve Pet CGM的商业化发布。

About ALR Technologies SG Ltd.

关于 ALR Technologies SG Ltd.

ALRT is a data management company that developed the ALRT Diabetes Solution, a comprehensive approach to diabetes care that includes an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices, and Predictive A1C algorithm to track treatment success between lab reports and an FDA-cleared Insulin Dosing Adjustment program.

ALRT 是一家数据管理公司，开发了 ALRT 糖尿病解决方案。该方案为糖尿病护理提供了一套综合方法，包括一个经美国食品药品监督管理局（FDA）许可且符合《健康保险流通与责任法案》（HIPAA）要求的糖尿病管理系统，该系统可直接从血糖仪和连续血糖监测设备收集数据；此外，还包括用于在两次实验室报告之间追踪治疗效果的预测性糖化血红蛋白（A1C）算法，以及一个经 FDA 许可的胰岛素剂量调整程序。

The overall goal is to optimize diabetes drug therapies to drive improved patient outcomes..

总体目标是优化糖尿病药物治疗，以改善患者预后。

In addition, the animal health division of ALRT has developed the GluCurve Pet CGM; a solution to assist veterinarians better determine the efficacy of insulin treatments and to help to identify the appropriate dose and frequency of administration for companion animals, thereby delivering the same optimization of diabetic drug therapies to pets as to humans..

此外，ALRT的动物健康部门开发了GluCurve宠物连续血糖监测系统（CGM）；该解决方案旨在协助兽医更准确地评估胰岛素治疗的效果，并帮助确定伴侣动物的合适剂量和给药频率，从而为宠物提供与人类相同的糖尿病药物治疗优化方案。

More information about ALRT and the GluCurve Pet CGM can be found at

有关 ALRT 和 GluCurve 宠物连续血糖监测仪的更多信息，请访问

www.alrt.com

www.alrt.com

and

和

www.GluCurve.com

www.GluCurve.com

in the USA or

在美国或

www.GluCurve.ca

www.GluCurve.ca

in Canada

在加拿大

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:

关于前瞻性信息的警示性声明：

This news release includes certain 'forward-looking statements' as defined under applicable securities legislation. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements.

本新闻稿包含适用证券立法所定义的某些“前瞻性陈述”。前瞻性陈述必然基于多项估计和假设，尽管这些估计和假设被认为合理，但仍受已知和未知的风险、不确定性及其他因素的影响，这些因素可能导致实际结果和未来事件与前瞻性陈述所明示或暗示的内容存在重大差异。

In particular, this news release contains forward-looking statements concerning the anticipated completion of the Transactions, the anticipated terms thereof, the anticipated timing thereof and the anticipated benefits thereof. ALRT has provided this information in reliance on certain assumptions that it believes are reasonable, including assumptions as to the timing of receipt of the necessary regulatory and other approvals and the satisfaction of and time necessary to satisfy the conditions to the closing of the Transactions.

特别是，本新闻稿包含有关交易预期完成时间、预期条款、预期时间安排以及预期收益的前瞻性陈述。ALRT 基于其认为合理的某些假设提供此信息，包括关于获得必要的监管及其他批准的时间安排，以及满足交易所需条件及完成这些条件所需时间的假设。

These dates may change for a number of reasons, including the inability to secure necessary regulatory, or other approvals in the time assumed, the inability to complete the equipment purchase, or the need for additional time to satisfy the conditions to the completion of the Transactions. The Company has entered into a Letter of Intent, there is no assurance that the Company will enter into the definitive agreements to complete the Transactions.

这些日期可能因多种原因而发生变化，包括无法在预期时间内获得必要的监管或其他批准、无法完成设备采购，或需要更多时间以满足完成交易的条件。本公司已签署意向书，但无法保证本公司将签订完成交易的最终协议。

In addition, there are no assurances the Transactions will be completed on the terms disclosed herein or at all or that if completed that ALRT will achieve the anticipated benefits thereof. Accordingly, readers should not place undue reliance on the forward-looking statements contained in this news release concerning the Transactions.

此外，无法保证交易将按照本文披露的条款完成，或根本无法完成，也无法保证若交易完成，ALRT 能够实现其预期收益。因此，读者不应过度依赖本新闻稿中有关交易的前瞻性陈述。

There can be no assu.

不可能有安慰。

SOURCE ALR Technologies SG Ltd.

来源：ALR Technologies SG Ltd.

21

二十一

%

%

more press release views with

更多新闻稿浏览量，借助

Request a Demo

申请演示